Hesperidin produces cardioprotective activity via PPAR-γ pathway in ischemic heart disease model in diabetic rats

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Agrawal, Yogeeta O ^a,b,c   Sharma, Pankaj Kumar ^a   Shrivastava, Birendra ^a   Ojha, Shreesh ^d   Upadhya, Harshita M ^e   Arya, Dharamvir Singh ^b   Goyal, Sameer N ^c  

^a JAIPUR NATIONAL UNIVERSITY   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c R C PATEL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

^d UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^e Sunil's Daibetes and Research Center   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE MB; GW 9962; HESPERIDIN; LACTATE DEHYDROGENASE; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PROTEIN BAX; PROTEIN BCL 2; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE; CARDIOTONIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OCCLUSION; DIABETES MELLITUS; ENZYME ACTIVITY; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMODYNAMIC PARAMETERS; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LIPID PEROXIDATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; HEART MUSCLE; HEMODYNAMICS; METABOLISM; MYOCARDIAL ISCHEMIA; PATHOLOGY; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE; WISTAR RAT;

ANILIDES; ANIMALS; BCL-2-ASSOCIATED X PROTEIN; CARDIOTONIC AGENTS; CREATINE KINASE, MB FORM; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; HEMODYNAMICS; HESPERIDIN; LIPID PEROXIDATION; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84934325023     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111212     Document Type: Article

References (43)

1. Lopez AD, Murrau CC (1998) The global burden disease, 1990-2020. Nat Med 4: 1241-1243.
2. Bibbins-Domingo K, Coxson P, Pletcher MJ, Lightwood J, Goldman L (2007) Adolescent overweight and future adult coronary heart disease. N Engl J Med 6: 2371-2379.
3. De Bono DP, Boon NA (1992) Diseases of the cardiovascular system. In: Edwards CRW, Boucheir IAS, editors. Davidson's Principles and Practice and Medicine. Churchill Livingstone, Hong Kong, pp. 249-340.
4. DeBiase L, Pignatelli P, Lenti L, TocciG, Piccioni F, et al. (2003) Enhanced TNF alpha and oxidative stress in patients with heart failure: effect of TNF alpha on platelet O2- production. Thromb Haemost 90: 317-325.
5. Rajadurai M, Prince PSM (2006) Preventive effect of naringin on lipid peroxides and antioxidants in isoproterenol induced cardiotoxicity in Wistar rats: Biochemical and histopathological evidences. Toxicology 228: 259-268.
6. Nakamura T, Nishi H, Kokusenya Y, Hirota K, Miura Y (2000) Mechanism of antioxidative activity of fluvastatin-determination of the active position. Chem Pharm Bull 48: 235-237.
7. Goyal SN, Bharti S, Bhatia J, Nag TC, Ray R, et al. (2011). Telmisartan, a dual ARB/partial PPAR-c agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes. Diabetes Obes Metab 13: 533-541.
8. Park HJ, Kim MJ, Ha E, Chung JH (2008) Apoptotic effect of hesperidin through caspase3 activation in human colon cancer cells, SNU-C4. Phytomedicine 15: 147-151.
9. Wilmsen PK, Spada DS, Salvador M (2005) Antioxidant activity of the flavonoid hesperidin in chemical and biological systems. J Agric Food Chem 53: 4757- 4761.
10. Gumieniczek A (2003) Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits. Life Sci 74: 553-562.
11. Salam NK, Huang TH, Kota BP, Kim MS, Li Y, et al. (2008) Novel PPARgamma agonists identified from a natural product library: A virtual screening, induced-fit docking and biological assay study. ChemBiol Drug Des 71: 57-70.
12. VandenHeuvel JP (1999) Peroxisome proliferator-activated receptors (PPARS) and carcinogenesis. Toxicol Sci 47: 1-8.
13. Hihi AK, Michalik L, Wahli W (2002) PPARs: Transcriptional effectors of fatty acids and their derivatives. Cell Mol Life Sci 59: 790-798.
14. Ondrey F (2009) Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res 15: 2-8.
15. Ito H, Nakano A, Kinoshita M, Matsumori A (2003) Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Invest 83: 1715-1721.
16. Okhawa H, Oohishi N, Yagi N (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95: 351-358.
17. Moron MS, Depierre JW, Mannervik B (1979) Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochem Biophys Acta 582: 67-78.
18. Singh AD, Amit S, Kumar OS, Rajan M, Mukesh N, et al. (2006) Cardioprotective effects of bosentan, a mixed endothelin type A and B receptor antagonist, during myocardial ischaemia and reperfusion in rats. Basic Clin Pharmacol Toxicol 98: 604-610.
19. Loh HK, Sahoo KC, Kishore K, Ray R, Nag TC, et al. (2007) Effects of thalidomide on isoprenaline- induced acute myocardial injury: A haemodynamic, histopathological and ultrastructural study. Basic Clin Pharmacol Toxicol 100: 233-239.
20. Mohanty IR, Arya DS, Gupta SK (2008) Withania somnifera provides cardioprotection and attenuates ischemia-reperfusion induced apoptosis. Clin Nutr 27: 635-642.
21. Mohanty I, Gupta SK, Arya DS (2007) Anti-apoptotic and cardioprotective effects of an herbal combination in rats with experimental myocardial infarction. Int J Integr Biol 1: 178-188.
22. Wu L, Wang R, De Champlain J, Wilson TW (2004) Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats. Am J Hypertens 17: 749-756.
23. Bolten CW, Payne MA, McDonald WG, Blanner PM, Chott RC, et al. (2007) Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive rat. DiabVasc Dis Res 4: 117-123.
24. de Oliveira Silva-Junior G, da Silva Torres T, de Souza Mendonca L, Alberto Mandarim-de-Lacerda C (2011) Rosiglitazone (peroxisome proliferator-activated receptor-gamma) counters hypertension and adverse cardiac and vascular remodeling in 2K1C hypertensive rats. Exp Toxicol Pathol 63: 1-7.
25. Geng DF, Wu W, Jin DM, Wang JF, Wu YM (2006) Effect of peroxisome proliferator-activated receptor gamma ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction. Int J Cardiol 113: 86-91.
26. CharanSahoo K, Arora S, Goyal S, Kishore K, Ray R, et al. (2009) Cardioprotective effects of benazepril, an angiotensin-converting enzyme inhibitor, in an ischaemia-reperfusion model of myocardial infarction in rats. J Renin Angiotensin Aldosterone Syst 10: 201-209.
27. Hagar HH (2002) Folic acid and vitamin B12 supplementation attenuates isoprenaline-induced myocardial infarction in experimental hyperhomocysteinemic rats. Pharmacol Res 46: 213-219.
28. Huang EJ, Kuo WW, Chen YJ, Chen TH, Chang MH, et al. (2006) Homocysteine and other biochemical parameters in type 2 diabetes mellitus with different diabetic duration or diabetic retinopathy. Clin Chim Acta 366: 293- 298.
29. Kakadiya J, Shah M, Shah N (2010) Effect of hesperidin on serum heart marker, myocardial tissues parameter and histopathological of heart in isoproterenol induced myocardial infarction in diabetic rats. Int J Biol Tech 1: 57-62.
30. Kakadiya J, Mulani H, Shah N (2010) Protective effect of hesperidin on cardiovascular complication in experimentally induced myocardial infarction in diabetes in rats. J Basic Clin Pharm 1: 85-91.
31. Dhalla NS, Elmoselhi AB, Hata T, Makino N (2000) Status of myocardial antioxidants in ischemia-reperfusion injury. Cardiovasc Res 47: 446-456.
32. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, et al. (2002) Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 16: 1027-1040.
33. Crow MT, Mani K, Nam YJ, Kitsis RN (2004) The mitochondrial death pathway and cardiac myocyte apoptosis. Circ Res 95: 957-970.
34. Liu HR, Tao L, Gao E, Lopez BL, Christopher TA, et al. (2004) Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res 62: 135-144.
35. Cao Z, Ye P, Long C, Chen K, Li X, et al. (2007) Effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on ischemiareperfusion injury in rats. Pharmacology 79: 184-192.
36. Ikejima H, Imanishi T, Tsujioka H, Kuroi A, Kobayashi K, et al. (2008) Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change. J Hypertens 26: 964-972.
37. Kobayashi N1, Ohno T, Yoshida K, Fukushima H, Mamada Y, et al. (2008) Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats. Am J Hypertens 21: 576-581.
38. Erlund I, Meririnne E, Alfthan G, Aro A (2001) Plasma kinetics and urinary excretion of the flA (2001) naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. J Nutr 131: 235-241.
39. Manach C, Morand C, Gil-Izquierdo A, Bouteloup-Demange C, Remesy C (2003) Bioavailability in humans of the flavanones hesperidin and narirutin after the ingestion of two doses of orange juice. Eur J Clin Nutr 57: 235-242.
40. Ameer B, Weintraub RA, Johnson JV, Yost RA, Rouseff RL (1996) Flavanone absorption after naringin, hesperidin, and citrus administration. Clin Pharmacol Ther 60: 34-40.
41. Matsumoto H, Ikoma Y, Sugiura M, Yano M, Hasegawa Y (2004) Identification and quantification of the conjugated metabolites derived from orally administered hesperidin in rat plasma. Food Chem 52: 6653-6659.
42. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L (2004) Polyphenols: food sources and bioavailability. Am J Clin Nutr 79: 727-747.
43. Yamamoto M, Jokura H, Hashizume K, Ominami H, Shibuya Y, et al. (2013) Hesperidin metabolite hesperetin-7-O-glucuronide, but not hesperetin-30-Oglucuronide, exerts hypotensive, vasodilatory, and anti-inflammatory activities. Food Funct 4: 1346-1351.